文献速递先天性心脏病外科瓣膜外科

Inspiris瓣膜植入原生右心室流出道与早期人工瓣膜反流相关

Use of the Inspiris valve in the native right ventricular outflow tract is associated with early prosthetic regurgitation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-04-22

本研究回顾性分析2018至2022年227例接受外科肺动脉瓣置换或管道置换的患者,经倾向性匹配70对后发现,Inspiris组2年免于瓣膜失败率及免于至少中度肺动脉瓣反流率均低于非Inspiris组,而肺动脉瓣狭窄与再干预率无差异;Inspiris植入原生右心室流出道时耐久性更差。

要点

  • Inspiris组2年免于瓣膜失败率53.5±9.3% vs 非Inspiris组78.5±5.9%(P=.03)。
  • Inspiris组2年免于至少中度肺动脉瓣反流率54.2±9.6% vs 非Inspiris组86.4±4.9%(P<.01)。
  • Inspiris植入原生右心室流出道18个月免于瓣膜失败率59.0±9.5% vs 作为管道85.9±9.5%(P=.03)。

核心结论

  • Inspiris瓣膜植入原生右心室流出道时早期耐久性差,其独特设计可能与顺应性肺动脉根部不兼容,作者建议可考虑改良植入技术或替代人工瓣膜。

研究设计与样本

  • 回顾性研究,纳入2018至2022年接受Inspiris或非Inspiris瓣膜/管道行肺动脉瓣置换或管道置换的患者,共227例,中位年龄19.3岁(四分位距11.8-34.4),Inspiris组120例(52.9%),非Inspiris组107例(47.1%),采用倾向性匹配识别70对患者。

主要发现

  • 中位随访26.6个月(四分位距12.4-41.1)。
  • 匹配患者中,Inspiris组2年免于瓣膜失败率53.5±9.3% vs 非Inspiris组78.5±5.9%(P=.03),Inspiris组较低。
  • 匹配患者中,Inspiris组2年免于至少中度肺动脉瓣反流率54.2±9.6% vs 非Inspiris组86.4±4.9%(P<.01),Inspiris组较低。
  • 匹配患者中,2年免于至少中度肺动脉瓣狭窄率两组无差异(P=.61),2年免于再干预率两组无差异(P=.92)。
  • Inspiris植入原生右心室流出道时18个月免于瓣膜失败率59.0±9.5% vs 作为管道时85.9±9.5%(P=.03),原生右心室流出道组较低。

临床怎么用

  • 作者认为Inspiris瓣膜植入原生右心室流出道时早期耐久性差,可考虑改良植入技术或替代人工瓣膜。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Inspiris Resilia prosthesis (Edwards Lifesciences) has been increasingly used in the pulmonic position with limited performance data. We sought to investigate its durability as a surgical pulmonary valve replacement (PVR). METHODS: We retrospectively reviewed patients who underwent PVR or conduit replacement with an Inspiris or non-Inspiris valve/conduit from 2018 to 2022. The primary end point was freedom from a composite of at least moderate pulmonary regurgitation, pulmonary stenosis, or valve/conduit reintervention. Secondary end points were individual components of the composite outcome. To account for baseline differences, propensity matching identified 70 patient pairs. RESULTS: A total of 227 patients (median age: 19.3 years [interquartile range, 11.8-34.4]) underwent PVR or conduit replacement (Inspiris: n = 120 [52.9%], non-Inspiris: n = 107 [47.1%]). Median follow-up was 26.6 months [interquartile range, 12.4-41.1]. Among matched patients, 2-year freedom from valve failure was lower in the Inspiris group (53.5 ± 9.3% vs 78.5 ± 5.9%, P = .03), as was freedom from at least moderate pulmonary regurgitation (54.2 ± 9.6% vs 86.4 ± 4.9%, P < .01). There was no difference in 2-year freedom from at least moderate pulmonary stenosis (P = .61) or reintervention (P = .92). Inspiris durability was poorer when implanted in the native right ventricular outflow tract compared with as a conduit, with 18-month freedom from valve failure of 59.0 ± 9.5% versus 85.9 ± 9.5% (P = .03). CONCLUSIONS: Early durability of the Inspiris valve is poor when implanted in the native right ventricular outflow tract; its unique design may be incompatible with the compliant pulmonary root. Modified implantation techniques or alternative prostheses should be considered.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nguyen SN, Vinogradsky AV, Sevensky R, et al. Use of the Inspiris valve in the native right ventricular outflow tract is associated with early prosthetic regurgitation. J Thorac Cardiovasc Surg. 2023. PMID: 37088131. doi:10.1016/j.jtcvs.2023.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。